Compare Citius Pharmaceuticals Inc (CTXR) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs MasTec Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while MasTec Inc trades at $220.47 (market cap $17.40B). The key difference: MasTec Inc is far larger — about 1277.5× Citius Pharmaceuticals Inc's market cap, and MasTec Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and MasTec Inc for 23 Days on average.
| CTXR | MTZ | |
|---|---|---|
Market Cap | $13.62M | $17.40B |
Volume | 132,438 | 1,415,821 |
Sector | Health | Industrials |
52-Week High | $1.82 | $437.51 |
52-Week Low | $0.48 | $190.08 |
Typical Hold Time | 16 Days | 23 Days |
Enterprise Value | $3.79M | $20.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
MasTec (MTZ) trades at $223.37, down 2.16% on the day, with technical indicators showing a neutral to bearish short-term bias. The company demonstrates strong fundamentals with Q1 2026 earnings beating expectations and a robust 88.9% analyst buy rating. Recent news highlights MTZ's positioning to benefit from infrastructure investment cycles, particularly in power delivery and data center markets, supported by a record $21.4 billion backlog.
The outlook remains positive given strong institutional support and infrastructure tailwinds, though premium valuation and communications segment softness pose risks. With a consensus price target of $408.58 representing 83% upside potential, the stock offers significant growth opportunity for investors comfortable with execution risks in the competitive infrastructure sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
